글로벌 활성화 응고 시간 테스트 시장 – 2030년까지의 산업 동향 및 예측

활성화된 응고 시간 테스트 시장 분석 및 규모

DIC(Disseminated Intravascular Coagulation)와 같은 응고 장애의 발생률은 기저 질환에 따라 다릅니다. 예를 들어, 패혈증 환자의 경우 DIC 발생률은 20%에서 50% 사이입니다. 심부정맥혈전증(DVT)의 연간 발생률은 1,000명당 약 1~2건으로 추산되는 반면, 폐색전증 (PE)의 연간 발생률은 1,000명당 약 0.5~1건입니다. 혈우병 A의 발생률은 5,000~10,000명의 남성 출생당 약 1건으로 추산되는 반면, 혈우병 B의 발생률은 30,000명의 남성 출생당 약 1건으로 더 낮습니다.

Data Bridge Market Research는 2022년에 4억 4,764만 달러였던 글로벌 활성화 응고 시간 검사 시장이 2030년까지 6억 4,393만 달러에 도달할 것으로 예상되며, 2023-2030년 예측 기간 동안 4.6%의 CAGR을 보일 것으로 분석했습니다. 이는 시장 가치를 나타냅니다. "임상 검사실 분석기"는 환자를 위한 더 좋고 정확한 진단 방법에 대한 수요가 증가함에 따라 글로벌 활성화 응고 시간 검사 시장의 제품 유형 부문을 지배하고 있습니다. 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

활성화된 응고 시간 테스트 시장 범위 및 세분화

시장 정의

활성화된 응고 시간(ACT)은 주로 비분획(표준) 헤파린 요법의 고용량을 모니터링하는 데 사용되는 검사입니다. 헤파린 은 혈액 응고를 방지하는 약물( 항응고제 )이며 일반적으로 주사 또는 연속 주입을 통해 정맥 주사(IV)로 투여됩니다. 심장 우회 수술과 같이 혈액 응고를 방지해야 하는 과정에서 고용량의 헤파린을 투여할 수 있습니다.

글로벌 활성화 응고 시간 테스트 시장 역학

운전자

• 심혈관 질환의 유병률 증가

심방세동, 심부정맥혈전증 , 관상동맥질환과 같은 심혈관 질환 은 전 세계적으로 이환율과 사망률에 크게 기여합니다. 이러한 질환이 있는 환자의 응고 시간을 정확하고 시기적절하게 모니터링해야 할 필요성이 ACT 검사에 대한 수요를 촉진합니다.

• 항응고제 치료에 대한 수요 증가

Anticoagulant medications, including heparin, are commonly used in the management and prevention of blood clotting disorders. ACT testing is essential to monitor the effectiveness and safety of anticoagulant therapy, ensuring that patients are within the desired therapeutic range.

• Rising Number of Surgical Procedures

Surgical procedures, including cardiac surgeries, vascular surgeries, and orthopedic surgeries, often require anticoagulation to prevent clot formation during and after the procedure. ACT testing is crucial in guiding the administration of heparin and monitoring clotting time to prevent bleeding complications.

• Increasing Geriatric Population

The aging population is prone to various cardiovascular conditions, leading to an increased need for ACT testing. Elderly individuals often require anticoagulant therapy and close monitoring of clotting time due to their higher risk of thromboembolic events.

Opportunities

• Increasing Adoption of Point-of-Care Testing

Point-of-care testing (POCT) is gaining popularity due to its ability to provide immediate results at the patient's bedside or in outpatient settings. ACT testing at the point of care offers the opportunity for rapid and real-time monitoring of clotting time, enabling prompt adjustments in anticoagulant therapy and reducing the risk of bleeding or thrombotic events.

• Advances in Technology and Automation

Technological advancements in ACT testing devices, including the development of automated systems, provide opportunities for improved accuracy, speed, and ease of use. Automation reduces human error, streamlines workflow, and enhances efficiency in ACT testing laboratories, thereby increasing adoption and demand for ACT testing.

Restraints/Challenges

• Limited Awareness and Adoption

Despite the importance of ACT testing in monitoring clotting time, there may be limited awareness and understanding among healthcare professionals and patients. Lack of education, training, and guidelines for appropriate utilization of ACT testing can hinder its adoption, leading to underutilization or inconsistent use.

• Competition from Alternative Tests

While ACT testing is widely used in certain clinical scenarios, there are alternative tests available for assessing clotting time, such as prothrombin time (PT) testing and activated partial thromboplastin time (APTT) testing. These tests may be more commonly used or preferred in certain settings, which can limit the demand for ACT testing.

• Limitations of Current Testing Methods

Existing ACT testing methods may have limitations in terms of accuracy, precision, and reproducibility. Variations in testing protocols, inter-laboratory variability, and challenges in standardization can affect the reliability and comparability of results. Overcoming these limitations and improving the performance of ACT testing methods is a challenge for manufacturers.

• Regulatory Challenges

The global ACT testing market is subject to regulatory requirements and guidelines that vary across different regions and countries. Compliance with these regulations, obtaining necessary approvals, and adhering to quality control standards can be complex and time-consuming, posing challenges for companies operating in multiple jurisdictions.

This global activated clotting time testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global activated clotting time testing market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth. 

Recent Developments

• In March 2021, Siemens Healthineers announced the launch of the ACTHemostasis System, a fully automated solution for ACT testing. The system offers rapid and accurate results, enhancing efficiency and workflow in coagulation testing
• In January 2021, Thermo Fisher Scientific introduced the HemosIL Liquid Heparin assay, a new reagent for ACT testing. The assay is designed to improve accuracy and precision in heparin monitoring during cardiac surgeries and other procedures

Global Activated Clotting Time Testing Market Scope

The global activated clotting time testing market is segmented on the basis of product type, application, technology, test and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Point of Care
• Clinical Laboratory Analyzer

Application

• Cardiovascular and Vascular Surgery
• ECMO
• Cardiac Catheterization Laboratories
• Critical Care Units
• Hemodialysis Units

Technology

• Optical Detection
• Laser Based Detection
• Mechanical Detection
• Fluorescent Based Detection

Test

• Prothrombin Time
• Fibrinogen
• Activated Partial Thromboplastin Time
• Activated Clotting Time
• D Dimer
• Platelet Function
• Heparin and Protamine Dose Response Test for ACT
• Others

End Users

• Hospitals
• Clinical Laboratories
• Ambulatory Surgical Centres
• Academic & Research Institutes

Global Activated Clotting Time Testing Market Regional Analysis/Insights

The global activated clotting time testing market is analyzed and market size insights and trends are provided by country, product type, application, technology, test and end users as referenced above.

The countries covered in the global activated clotting time testing market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa.

North America dominates the global activated clotting time testing market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having risk of bleeding or thrombotic complications.    

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for diagnosis and treatment procedures, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global activated clotting time testing market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global activated clotting time testing market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global activated clotting time testing market. The data is available for historic period 2015-2020.

Competitive Landscape and Global Activated Clotting Time Testing Market Share Analysis

글로벌 활성화 응고 시간 테스트 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭 및 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 글로벌 활성화 응고 시간 테스트 시장과 관련된 회사의 초점에만 관련이 있습니다. 

글로벌 활성화 응고 시간 테스트 시장에서 운영되는 주요 업체는 다음과 같습니다.

• F. 호프만-라 로슈 유한회사(스위스)
• 지멘스(독일)
• Thermo Fisher Scientific(미국)
• 애벗(미국)
• 헬레나 연구소 주식회사(미국)
• 시스멕스 주식회사(일본)
• NIHON KOHDEN CORPORATION (일본)
• Instrumentation Laboratory India Pvt Ltd(인도)
• 메드트로닉(아일랜드)
• Diagnostica Stago SAS(프랑스)
• WerfenLife, SA(스페인)
• Laboratory Corporation of America Holdings. (미국)
• 다나허. (미국)
• 호리바 주식회사(일본)
• 하이셀 메디컬(프랑스)
• Meril Life Sciences Pvt. Ltd. (인도)
• ACON(미국)
• BIO GROUP MEDICAL SYSTEM (캐나다)
• 베이징 석시더 테크놀로지 주식회사(중국)
• Maccura Biotechnology Co. (중국)

SKU-39444